Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) EBITDA Margin (2020 - 2025)

Foghorn Therapeutics (FHTX) has 5 years of EBITDA Margin data on record, last reported at 690.76% in Q4 2024.

  • For Q4 2024, EBITDA Margin fell 29140.0% year-over-year to 690.76%; the TTM value through Dec 2024 reached 378.99%, down 10007.0%, while the annual FY2024 figure was 378.99%, 10007.0% down from the prior year.
  • EBITDA Margin reached 690.76% in Q4 2024 per FHTX's latest filing, down from 235.96% in the prior quarter.
  • Across five years, EBITDA Margin topped out at 77.35% in Q3 2023 and bottomed at 63617.07% in Q3 2021.
  • Average EBITDA Margin over 5 years is 6017.21%, with a median of 661.07% recorded in 2022.
  • Peak YoY movement for EBITDA Margin: plummeted -5335618bps in 2021, then skyrocketed 6320339bps in 2022.
  • A 5-year view of EBITDA Margin shows it stood at 8272.91% in 2020, then skyrocketed by 51bps to 4083.73% in 2021, then surged by 84bps to 669.41% in 2022, then soared by 40bps to 399.36% in 2023, then tumbled by -73bps to 690.76% in 2024.
  • Per Business Quant database, its latest 3 readings for EBITDA Margin were 690.76% in Q4 2024, 235.96% in Q3 2024, and 331.3% in Q2 2024.